![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
|
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
3MB | |
|
PDF (Supplementary Information)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
330kB |
| Item Type: | Article |
|---|---|
| Title: | Lösliche Guanylatzyklase(sGC)-Stimulation mit Vericiguat: Von der pharmakologischen Idee bis zur Therapie der chronischen Herzinsuffizienz [Soluble guanylate cyclase (sGC) stimulation with vericiguat : from the pharmacological idea to the treatment of chronic heart failure] |
| Creators Name: | Haase, N. and Kedziora, S.M. and Mueller, D.N. and Dechend, R. |
| Abstract: | BACKGROUND: According to the new European Society of Cardiology (ESC) guidelines on the diagnostics and treatment of acute and chronic heart failure, vericiguat (Verquvo®) can be included in the treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction who, despite standard treatment after a recently occurring decompensation event, were stabilized with the necessary intravenous (i.v.) therapy. OBJECTIVE: This review article summarizes the development of vericiguat, a soluble guanylate cyclase stimulator (sGC stimulator), which is a good example for the stringent implementation of a novel pharmacological therapy approach into treatment of heart failure. It provides valuable approaches for the practical use via the characterization of this patient collective that was investigated for the first time. RESULTS: The two relevant trials in the clinical development program for vericiguat, SOCRATES-Reduced and VICTORIA, have clearly demonstrated the efficacy and safety of vericiguat. The primary efficacy endpoint in the VICTORIA study “cardiovascular death or hospitalization due to heart failure” was significantly reduced in the vericiguat arm compared to placebo. Relevant subgroup analyses as well as safety data confirm this result and support the safe use in this high-risk population. CONCLUSION: The presented data allow the conclusion that vericiguat can be efficaciously and safely added to an existing treatment with a recommended standard medication for heart failure. It can be expected that in the routine practice the target dose of 10 mg can be reliably reached and maintained. Vericiguat should be regarded as a novel, easy and safe treatment option in a vulnerable patient population, for which there was previously hardly any medicinal treatment option. |
| Keywords: | Heart Failure with Reduced Ejection Fraction, Guideline-Based Therapy, Soluble Guanylate Cyclase Stimulator, Decompensation Event, Personalised Medicine |
| Source: | Kardiologie |
| ISSN: | 2731-7129 |
| Publisher: | Springer |
| Volume: | 16 |
| Number: | 6 |
| Page Range: | 466-478 |
| Date: | December 2022 |
| Official Publication: | https://doi.org/10.1007/s12181-022-00576-y |
Repository Staff Only: item control page
Download Statistics
Download Statistics
